Related references
Note: Only part of the references are listed.Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - YES
Jeremy Chataway
MULTIPLE SCLEROSIS JOURNAL (2017)
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study
Marcus D'Souza et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
Patrick Vermersch et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis
Diego Cadavid et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes
Luis Ruano et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - YES
Jeremy Chataway
MULTIPLE SCLEROSIS JOURNAL (2017)
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study
Marcus D'Souza et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
Patrick Vermersch et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis
Diego Cadavid et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes
Luis Ruano et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
Peter Feys et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Robert W. Motl et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis
Laura J. Balcer et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
Ralph H. B. Benedict et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
Peter Feys et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Robert W. Motl et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis
Laura J. Balcer et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
Ralph H. B. Benedict et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin et al.
LANCET (2016)
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
Ayman Tourbah et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
Ayman Tourbah et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Defining reliable disability outcomes in multiple sclerosis
Tomas Kalincik et al.
BRAIN (2015)
On the origin of Neurostatus
Ludwig Kappos et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis
Sandra Meyer-Moock et al.
BMC NEUROLOGY (2014)
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial
David M. Erlanger et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan
Richard A. Rudick et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Composite end points to assess delay of disability progression by MS treatments
J. Zhang et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis
Jeffrey A. Cohen et al.
JAMA NEUROLOGY (2014)
Accelerometry as a measure of walking behavior in multiple sclerosis
R. W. Motl et al.
ACTA NEUROLOGICA SCANDINAVICA (2013)
Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis
Yvonne C. Learmonth et al.
BMC NEUROLOGY (2013)
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial
John Zajicek et al.
LANCET NEUROLOGY (2013)
The reliability, precision and clinically meaningful change of walking assessments in multiple sclerosis
Yvonne C. Learmonth et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Disability in multiple sclerosis A reference for patients and clinicians
Ilya Kister et al.
NEUROLOGY (2013)
How People with Multiple Sclerosis Rate Their Quality of Life: An EQ-5D Survey via the UK MS Register
Kerina H. Jones et al.
PLOS ONE (2013)
Patient Reported Outcomes (PROs) in Clinical Trials: Is 'In-Trial' Guidance Lacking? A Systematic Review
Derek G. Kyte et al.
PLOS ONE (2013)
Brief International Cognitive Assessment for MS (BICAMS): international standards for validation
Ralph H. B. Benedict et al.
BMC NEUROLOGY (2012)
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2012)
The effects of clinical interventions on health-related quality of life in multiple sclerosis: a meta-analysis
Ayse Kuspinar et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures
D. Ontaneda et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Reliability and clinical significance of mobility and balance assessments in multiple sclerosis
Yvonne C. Learmonth et al.
INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH (2012)
Comparison of the Psychometric Properties of Two Fatigue Scales in Multiple Sclerosis
Dagmar Amtmann et al.
REHABILITATION PSYCHOLOGY (2012)
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
A. Novotna et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Safety and Feasibility of Autologous Bone Marrow Cellular Therapy in Relapsing-Progressive Multiple Sclerosis
C. M. Rice et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Integration of Cognitive Impairment in the Expanded Disability Status Scale of 215 Patients with Multiple Sclerosis
Helene Brissart et al.
EUROPEAN NEUROLOGY (2010)
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks
S. A. Morrow et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study
Maria P. Amato et al.
MULTIPLE SCLEROSIS (2010)
MRI and cognition in multiple sclerosis
M. Filippi et al.
NEUROLOGICAL SCIENCES (2010)
Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity
E. M. Mowry et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2009)
Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls
Myla D. Goldman et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Validation of the multiple sclerosis international quality of life questionnaire
M. C. Simeoni et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
The longitudinal relationship between the patient-reported multiple sclerosis impact scale and the clinician-assessed multiple sclerosis functional composite
L. Costelloe et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test
B. A. Parmenter et al.
MULTIPLE SCLEROSIS JOURNAL (2007)
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACHMS)
Ralph H. B. Benedict et al.
JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY (2006)
Confirming the validity and responsiveness of the multiple sclerosis walking scale-12 (MSWS-12)
C McGuigan et al.
NEUROLOGY (2004)
Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability
ELJ Hoogervorst et al.
MULTIPLE SCLEROSIS (2004)
Effect of relapses on development of residual deficit in multiple sclerosis
FD Lublin et al.
NEUROLOGY (2003)
Incorporating the patient's perspective into drug development and communication: An ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the Food and Drug Administration, February 16, 2001
C Acquadro et al.
VALUE IN HEALTH (2003)
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
JA Cohen et al.
NEUROLOGY (2002)
Quality of life in multiple sclerosis: the impact of depression, fatigue and disability
MP Amato et al.
MULTIPLE SCLEROSIS JOURNAL (2001)
The SF-36 in multiple sclerosis: why basic assumptions must be tested
J Hobart et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2001)
Developing a disease-specific quality of life measure for people with multiple sclerosis
HL Ford et al.
CLINICAL REHABILITATION (2001)
The Multiple Sclerosis Impact Scale (MSIS-29) - A new patient-based outcome measure
J Hobart et al.
BRAIN (2001)
Kurtzke scales revisited: the application of psychometric methods to clinical intuition
J Hobart et al.
BRAIN (2000)
Share Paper
